Entera Bio (NASDAQ:ENTX) Releases Earnings Results, Beats Estimates By $0.02 EPS

Entera Bio (NASDAQ:ENTX) released its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02, Zacks reports. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million.

Entera Bio Stock Down 2.6 %

ENTX opened at $1.75 on Friday. Entera Bio has a twelve month low of $1.41 and a twelve month high of $3.35. The company’s 50-day moving average price is $2.14 and its two-hundred day moving average price is $2.02. The stock has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a research note on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.